(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers
Autor(es) : Paolucci, G. (G.)
Pileri, S.A. (S.A.)
Pession, A. (A.)
Zinzani, P.L. (P.L.)
Rodriguez-Calvillo, M. (Mercedes)
Inoges, S. (Susana)
Sartini, R. (R.)
Turi, C. (C.)
Botti, S. (S.)
Maffei, R. (R.)
Tonelli, R. (R.)
Bendandi, M. (Maurizio)
Palabras clave : Tumor-specific
PCR
Follicular lymphoma
Consensus primers
CDR3
Fecha incorporación: 2001
Editorial : Oxford University Press
Versión del editor: http://annonc.oxfordjournals.org/content/12/10/1479.long
ISSN: 1569-8041
Cita: Bendandi M, Tonelli R, Maffei R, Botti S, Turi C, Sartini R, et al. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann Oncol 2001 Oct;12(10):1479-1484.
Resumen
Abstract BACKGROUND: The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning. PATIENTS AND METHODS: In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific VH CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures. RESULTS: The tumor-specific VH CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific VH CDR3 was also found in at least 8 of 10 of them. CONCLUSIONS: The proposed method allows the ability to quickly identify the B-cell tumor-specific VH CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.
Enlace permanente: http://hdl.handle.net/10171/19954
Aparece en las colecciones: DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Ficheros en este registro:
Fichero:  Ann Oncol _12 2001.pdf
Descripción: 
Tamaño:  1,56 MB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.